Citations

Clear

3042 citation(s) found for "Kumar, S".

Are we there yet with patent foramen ovale closure for secondary prevention in cryptogenic stroke? A systematic review and meta-analysis of randomized trials
Agasthi, Pradyumna , Kolla, Kantha R. , Yerasi, Charan , Tullah, Sibghat, Pulivarthi, Venkata Siva Krishna Kumar, Louka, Boshra, Mookadam, Farouk , Fortuin, F. David , Kolla, Kantha Ratnam, Pulivarthi, Venkata Siva, Arsanjani, Reza , Yang, Eric H.

Mayo Clinic

SAGE Open Medicine | February 5, 2019 | Volume: 7 | Issue: No issue available | Pages: No page available

10.1177/2050312119828261 | PMID 30783525 Get It

Background: We performed a meta-analysis to evaluate the benefit of patent foramen ovale closure in stroke prevention. Methods: We searched Medline/PubMed, EMBASE, Web of Science and Cochrane central database for randomized control trials assessing the incidence of recurrent stroke after patent foramen ovale closure when compared to medical therapy. Pooled odds ratio and 95% confidence intervals were calculated using a random effects model. The heterogeneity among studies was tested using the χ 2 test and inconsistency was quantified using the I 2 statistic. Results: Our search strategy yielded 71 articles. We included five studies with a total of 3440 patients. Median age in the device group was 45 (43, 5.5) years and in the medical group was 45 (44.5, 46) years; 52% were male, 27.7% of patients had an atrial septal aneurysm, 25% had hypertension, and 20.5% had diabetes mellitus. The median follow-up time was 44 (34.5–50) months. The pooled odds ratio of recurrent stroke, transient ischemic attack and composite end point of stroke + transient ischemic attack + peripheral embolism in the patent foramen ovale closure versus medical therapy group were 0.4 (95% confidence interval 0.25–0.63, I 2 = 57.5%), 0.93 (95% confidence interval 0.61–1.42, I 2 = 0%), and 0.6 (95% confidence interval 0.44–0.82, I 2 = 0%), respectively. The incidence of atrial fibrillation was found to be significantly higher in the patent foramen ovale closure group with odds ratio of 6 (95% confidence interval 3.13–11.4, I 2 = 33.5%). On subgroup analysis, patent foramen ovale closure appeared to benefit males and patients with a large shunt. Number needed to treat to prevent one recurrent stroke with patent foramen ovale closure is 42. Number needed to harm to cause one atrial fibrillation with patent foramen ovale closure is 39. Conclusion: This meta-analysis of randomized trials concludes that percutaneous patent foramen ovale closure is effective in recurrent stroke prevention especially in males and in those with a large shunt.
Uncommon Intraluminal Tumors of the Gallbladder and Biliary Tract: Spectrum of Imaging Appearances
Chatterjee, Argha , Vendrami, Camila Lopes , Bandy, Andrew , Menias, Christine O. , Hammond, Nancy A., Yaghmai, Vahid , Miller, Frank H. , Lopes Vendrami, Camila, Nikolaidis, Paul, Mittal, Pardeep K, Bandy, Andrew J, Yang, Guang-Yu, Miller, Frank H , Nikolaidis, Paul , Mittal, Pardeep Kumar , Yang, Guang‐Yu

Mayo Clinic

RadioGraphics | February 1, 2019 | Volume: 39 | Issue: 2 | Pages: 388-412

10.1148/rg.2019180164 | PMID 30707646 Get It

Faculty Opinions recommendation of Vitamin D supplements and prevention of cancer and cardiovascular disease.
Kumar, Rajiv

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 30, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.734412767.793555624 Get It

An open-label phase Ib/2 trial of TRC105 plus sorafenib in patients with advanced/metastatic hepatocellular carcinoma (HCC) (NCT01806064).
Mody, Kabir , Simpson, Brian E, Adams, Bonne J., Theuer, Charles P. , Raghav, Kanwal , Lee, Richard T. , Paluri, Ravi Kumar , Kaseb, Ahmed O

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 268-268

10.1200/jco.2019.37.4_suppl.268 Get It

268 Background: TRC105, an endoglin antibody, potentiates the activity of sorafenib (S) in preclinical HCC models, and TRC105 + S demonstrated a 33% partial response rate (5/15 pts) by RECIST, at RP2D doses of TRC105 in HCC pts ( Clin Can Res 2017). Adverse events characteristic of each drug were not increased in frequency or severity when the two drugs were administered concurrently. Methods: P1: Compare wkly TRC105 dosing vs four wkly doses followed by every other wkly dosing + S 800 mg daily. P2: Four objective responses are required in 21 pts to reject the null hypothesis that the true response rate probability is < 5% with an alpha level of 0.1 and 80% power. Key inclusion criteria: disease not amendable to surgical or local therapies, ECOG ≤ 1; Child-Pugh A or B (7 points) classification. Results: Thirteen pts were enrolled in phase 1b at TRC105 10 mg/kg wkly for four doses and 15 mg/kg every other week thereafter + S. Mean serum levels of TRC105 exceeded the target conc. following 4 wkly doses of TRC105 at 10 mg/kg (mean = 34 µg/ml, range BLOQ-80). Mean trough conc. decreased following every other week dosing (mean = 13 µg/ml, range BLOQ-31), resulting in infusion reactions or a continued requirement for premedication. Therefore, wkly dosing of TRC105 at 10 mg/kg is the recommended Phase 2 dose. ADA were detected in 10 of 14 pts and correlated with lower than expected PK conc. Common TRC105 related AEs included ≤ G2 epistaxis, ≤ G2 fatigue and ≤ G2 headache. Common S related AEs included ≤ G3 fatigue, ≤ G3 hand foot syndrome and ≤G2 epistaxis. A total of 3 out of 14 evaluable patients (21%) enrolled in phase 1 and 2 achieved durable PR, 2 of these ongoing at week 45 and 17. Conclusions: TRC105 dosed at 10 mg/kg wkly was required to achieve target conc. due to higher clearance in HCC pts, which may have been influenced by a higher rate of ADA compared to studies of TRC105 in other tumor types. The combination of TRC105 + S demonstrated encouraging signs of activity, including durable PR in 2/9 evaluable pts in Phase 1b and 1/5 pts thus far in Phase 2. An additional 16 pts will be enrolled at the RP2D to assess the primary endpoint of ORR by RECIST. Clinical trial information: NCT01806064.
Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma
Sidana, Surbhi , Jevremović, Dragan , Tandon, Nidhi , Greipp, Patricia T. , Gertz, Morie A. , Rajkumar, S. Vincent , Kumar, Shaji , Tandon, Nidhi , Gertz, Morie A , Rajkumar, S Vincent , Jevremovic, Dragan , Sidana, Surbhi , Greipp, Patricia T , Ketterling, Rhett P. , Baughn, Linda B. , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | January 25, 2019 | Volume: 94 | Issue: 5 | Pages: No page available

10.1002/ajh.25420 | PMID 30680770 Get It

Transtracheal Jet Ventilation in Management of the Difficult Airway
McHugh, R Kathryn, Kumar, M. R. Anil , Mchugh, R., Šprung, Juraj , Bourke, David

Mayo Clinic

Anaesthesia and Intensive Care | January 22, 2019 | Volume: 35 | Issue: 3 | Pages: 406-408

10.1177/0310057x0703500315 | PMID 17591137 Get It

We present the use of transtracheal jet ventilation in two uncooperative patients with a difficult airway. Although transtracheal jet ventilation is considered as a last resort option in the difficult airway algorithm, its use can be a valuable tool in selected difficult airway situations. Transtracheal jet ventilation can effectively maintain arterial oxygenation and provide extra time for attempts to intubate the trachea, either directly or fibreoptically.
Evidence for a bind-then-bend mechanism for architectural DNA binding protein yNhp6A
Zvoda, Viktoriya, Holte, Molly Nelson, Becker, Nicole A. , Peters, Justin P. , Maher, L. James, Ansari, Anjum , Sarangi, Manas Kumar

Mayo Clinic

Nucleic Acids Research | January 18, 2019 | Volume: 47 | Issue: 6 | Pages: 2871-2883

10.1093/nar/gkz022 | PMID 30698746 Get It

Outcomes of young patients with Waldenstrom macroglobulinemia (WM).
Vallumsetla, Nishanth, Ansell, Stephen M. , Lacy, Martha Q. , Hayman, Suzanne R. , Kyle, Robert A. , Kumar, Shaji , Kapoor, Prashant , Paludo, Jonas , Gertz, Morie A. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8609-8609

10.1200/jco.2014.32.15_suppl.8609 Get It